These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31953867)

  • 1. Low incidence of posttransplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab.
    Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Ogata M; Sugio Y; Fukuda T; Uchida N; Ikegame K; Matsuoka KI; Shiratori S; Kondo T; Miyamoto T; Eto T; Ichinohe T; Kanda Y; Atsuta Y; Suzuki R;
    Hematol Oncol; 2020 Apr; 38(2):146-152. PubMed ID: 31953867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.
    Kinch A; Hallböök H; Arvidson J; Sällström K; Bondeson K; Pauksens K
    Leuk Lymphoma; 2018 May; 59(5):1172-1179. PubMed ID: 28831836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors and Predictive Scoring System For Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation.
    Fujimoto A; Hiramoto N; Yamasaki S; Inamoto Y; Uchida N; Maeda T; Mori T; Kanda Y; Kondo T; Shiratori S; Miyakoshi S; Ishiyama K; Ikegame K; Matsuhashi Y; Tanaka J; Ichinohe T; Atsuta Y; Ogata M; Suzuki R
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1441-1449. PubMed ID: 30794929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical Analysis of Post-Transplant Lymphoproliferative Disorder after Hematopoietic Stem Cell Transplantation in Severe Aplastic Anemia Patients].
    Yan HM; Zheng XL; Zhu L; Ding L; Han DM; Liu J; Xue M; Li S; Wang HX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1224-1229. PubMed ID: 35981389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
    Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
    Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation: a single-center experience.
    Luo L; Zhang L; Cai B; Li H; Huang W; Jing Y; Zhu H; Zhao Y; Bo J; Wang Q; Han X; Yu L; Gao C
    Ann Transplant; 2014 Jan; 19():6-12. PubMed ID: 24399278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A clinical study of lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation].
    Xu LP; Huang XJ; Liu DH; Chen YH; Shi HX; Chen DB
    Zhonghua Nei Ke Za Zhi; 2007 Dec; 46(12):996-9. PubMed ID: 18478915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epstein-Barr Virus-Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical Outcomes.
    Xu LP; Zhang CL; Mo XD; Zhang XH; Chen H; Han W; Chen YH; Wang Y; Yan CH; Wang JZ; Wang FR; Zhao T; Liu YR; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2185-2191. PubMed ID: 26253005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X; Zhu Q; Qiu H; Chen F; Xue S; Ma X; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):138-43. PubMed ID: 27014984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.
    Chen DB; Liu XY; Kong FZ; Jiang Q; Shen DH
    J Clin Pathol; 2021 Nov; 74(11):697-703. PubMed ID: 34011618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation: a case report, meta-analysis, and systematic review.
    Su YY; Yu YF; Yan ZY; Zhao YJ; Lou JW; Xue F; Xu M; Feng Q; Ji XB; Dong XY; Wang W; Liu CF; Peng J; Liu XG
    Diagn Pathol; 2024 Sep; 19(1):122. PubMed ID: 39244586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis on anti-CD20 antibody-treated Epstein-Barr virus-related posttransplantation lymphoproliferative disorder following ATG-based haploidentical T-replete hematopoietic stem cell transplantation.
    Luo XY; Mo XD; Xu LP; Zhang XH; Wang Y; Liu KY; Chang YJ; Zhao XY; Huang XJ
    Ann Hematol; 2020 Nov; 99(11):2649-2657. PubMed ID: 32206854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic rituximab prevents EBV PTLD in haplo-cord transplant recipients at high risk.
    Van Besien K; Bachier-Rodriguez L; Satlin M; Brown MA; Gergis U; Guarneri D; Hsu J; Phillips AA; Mayer SA; Singh AD; Soave R; Rossi A; Small CB; Walsh TJ; Rennert H; Shore TB
    Leuk Lymphoma; 2019 Jul; 60(7):1693-1696. PubMed ID: 30741059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J; Gil L; Tridello G; Ljungman P; Donnelly JP; van der Velden W; Omar H; Martino R; Halkes C; Faraci M; Theunissen K; Kalwak K; Hubacek P; Sica S; Nozzoli C; Fagioli F; Matthes S; Diaz MA; Migliavacca M; Balduzzi A; Tomaszewska A; Camara Rde L; van Biezen A; Hoek J; Iacobelli S; Einsele H; Cesaro S;
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation.
    Sundin M; Le Blanc K; Ringdén O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
    Haematologica; 2006 Aug; 91(8):1059-67. PubMed ID: 16885046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The risk factors of post-transplant lymphoproliferative disorders following haploidentical hematopoietic stem cell transplantation].
    Zhang C; Huang X; Liu D; Mo X; Zhang X; Chen H; Han W; Chen Y; Wang Y; Wang J; Wang F; Zhao T; Liu Y; Liu K; Xu L
    Zhonghua Nei Ke Za Zhi; 2014 Jul; 53(7):527-31. PubMed ID: 25264006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophagocytic lymphohistiocytosis is a sign of poor outcome in pediatric Epstein-Barr virus-associated post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation.
    Ali S; AlThubaiti S; Renzi S; Krueger J; Chiang KY; Naqvi A; Schechter T; Punnett A; Ali M
    Pediatr Transplant; 2019 Feb; 23(1):e13319. PubMed ID: 30417487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
    Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
    J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.